Kan Liyen Katrina, Drummond Kate, Hunn Martin, Williams David, O'Brien Terence J, Monif Mastura
Department of Neuroscience, Monash University Faculty of Medicine, Nursing and Health Sciences, Melbourne, Victoria, Australia.
Department of Physiology, The University of Melbourne, Melbourne, Victoria, Australia.
BMJ Neurol Open. 2020 Aug 24;2(2):e000069. doi: 10.1136/bmjno-2020-000069. eCollection 2020.
Gliomas are the most common central nervous system malignancies and present with significant morbidity and mortality. Treatment modalities are currently limited to surgical resection, chemotherapy and radiotherapy. Increases in survival rate over the previous decades are negligible, further pinpointing an unmet clinical need in this field. There is a continual struggle with the development of effective glioma diagnostics and therapeutics, largely due to a multitude of factors, including the presence of the blood-brain barrier and significant intertumoural and intratumoural heterogeneity. Importantly, there is a lack of reliable biomarkers for glioma, particularly in aiding tumour subtyping and measuring response to therapy. There is a need for biomarkers that would both overcome the complexity of the disease and allow for a minimally invasive means of detection and analysis. This is a comprehensive review evaluating the potential of current cellular, proteomic and molecular biomarker candidates for glioma. Significant hurdles faced in glioma diagnostics and therapy are also discussed here.
胶质瘤是最常见的中枢神经系统恶性肿瘤，具有较高的发病率和死亡率。目前的治疗方式仅限于手术切除、化疗和放疗。与过去几十年相比，生存率的提高微乎其微，这进一步凸显了该领域尚未满足的临床需求。在有效胶质瘤诊断和治疗方法的开发方面一直存在困难，这主要是由于多种因素，包括血脑屏障的存在以及肿瘤间和肿瘤内的显著异质性。重要的是，缺乏可靠的胶质瘤生物标志物，尤其是在辅助肿瘤亚型分类和评估治疗反应方面。需要能够克服疾病复杂性并允许采用微创检测和分析方法的生物标志物。这是一篇全面的综述，评估了当前胶质瘤细胞、蛋白质组学和分子生物标志物候选物的潜力。本文还讨论了胶质瘤诊断和治疗中面临的重大障碍。
